GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (NAS:ACHV) » Definitions » Piotroski F-Score
中文

Achieve Life Sciences (Achieve Life Sciences) Piotroski F-Score

: 2 (As of Today)
View and export this data going back to 1995. Start your Free Trial

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Achieve Life Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Achieve Life Sciences's Piotroski F-Score or its related term are showing as below:

ACHV' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 3   Max: 4
Current: 2

During the past 13 years, the highest Piotroski F-Score of Achieve Life Sciences was 4. The lowest was 1. And the median was 3.


Achieve Life Sciences Piotroski F-Score Historical Data

The historical data trend for Achieve Life Sciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 4.00 1.00 2.00 2.00

Achieve Life Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 2.00 2.00

Competitive Comparison

For the Biotechnology subindustry, Achieve Life Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -8.992 + -8.239 + -7.108 + -5.476 = $-29.82 Mil.
Cash Flow from Operations was -8.303 + -6.676 + -5.136 + -4.364 = $-24.48 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(29.971 + 20.798 + 28.915 + 24.337 + 19.371) / 5 = $24.6784 Mil.
Total Assets at the begining of this year (Dec22) was $29.97 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.
Total Current Assets was $16.98 Mil.
Total Current Liabilities was $20.81 Mil.
Net Income was -7.573 + -10.468 + -13.077 + -11.232 = $-42.35 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(47.516 + 40.614 + 33.985 + 23.723 + 29.971) / 5 = $35.1618 Mil.
Total Assets at the begining of last year (Dec21) was $47.52 Mil.
Long-Term Debt & Capital Lease Obligation was $0.07 Mil.
Total Current Assets was $27.33 Mil.
Total Current Liabilities was $21.60 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Achieve Life Sciences's current Net Income (TTM) was -29.82. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Achieve Life Sciences's current Cash Flow from Operations (TTM) was -24.48. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-29.815/29.971
=-0.99479497

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-42.35/47.516
=-0.89127873

Achieve Life Sciences's return on assets of this year was -0.99479497. Achieve Life Sciences's return on assets of last year was -0.89127873. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Achieve Life Sciences's current Net Income (TTM) was -29.82. Achieve Life Sciences's current Cash Flow from Operations (TTM) was -24.48. ==> -24.48 > -29.82 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.006/24.6784
=0.00024313

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.069/35.1618
=0.00196236

Achieve Life Sciences's gearing of this year was 0.00024313. Achieve Life Sciences's gearing of last year was 0.00196236. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=16.982/20.813
=0.81593235

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=27.33/21.599
=1.26533636

Achieve Life Sciences's current ratio of this year was 0.81593235. Achieve Life Sciences's current ratio of last year was 1.26533636. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Achieve Life Sciences's number of shares in issue this year was 21.18. Achieve Life Sciences's number of shares in issue last year was 13.569. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Achieve Life Sciences's gross margin of this year was . Achieve Life Sciences's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/29.971
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/47.516
=0

Achieve Life Sciences's asset turnover of this year was 0. Achieve Life Sciences's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Achieve Life Sciences has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Achieve Life Sciences  (NAS:ACHV) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Achieve Life Sciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (Achieve Life Sciences) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.
Executives
John Bencich officer: CFO and PFO 2401 FOURTH AVENUE, SUITE 1050, SEATTLE WA 98121
Stuart Duty director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Sellig director 22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Thomas Braxton King director 91 JAMES AVENUE, ATHERTON CA 94027
Dialectic Life Sciences Spv Llc 10 percent owner C/O DIALECTIC LS MANAGER LLC, 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Ls Manager Llc 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
John Fichthorn 10 percent owner C/O DIALECTIC CAPITAL MANAGEMENT, LLC, 17 STATE STREET, SUITE 3930, NEW YORK NY 10004
Dialectic Capital Management, Lp 10 percent owner 119 ROWAYTON AVENUE, 2ND FLOOR, NORWALK CT 06853
Dialectic Partners, Llc 10 percent owner 2ND FLOOR 119 ROWAYTON AVE, NORWALK CT 06853
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Financial Group Svb 10 percent owner 2270 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025
Svb Innovation Credit Fund Viii, L.p. 10 percent owner C/O SVB INNOVATION CREDIT PARTNERS VIII, 2770 SAND HILL ROAD, MENLO PARK CA 94025
Innovation Credit Fund Viii-a, L.p. 10 percent owner 2770 SAND HILL ROAD, MENLO PARK CA 94025
Svb Innovation Credit Partners Viii-a, Llc 10 percent owner 2770 SAND HILL ROAD, MENLO CITY CA 94025

Achieve Life Sciences (Achieve Life Sciences) Headlines